KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Net Cash Flow (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Net Cash Flow for 16 consecutive years, with -$356.0 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Net Cash Flow fell 118.55% year-over-year to -$356.0 million, compared with a TTM value of -$4.0 billion through Dec 2024, down 1007.82%, and an annual FY2025 reading of $5.6 billion, up 240.49% over the prior year.
  • Net Cash Flow was -$356.0 million for Q4 2024 at Thermo Fisher Scientific, up from -$2.6 billion in the prior quarter.
  • Across five years, Net Cash Flow topped out at $5.4 billion in Q4 2022 and bottomed at -$7.8 billion in Q4 2021.
  • Average Net Cash Flow over 5 years is $78.0 million, with a median of $978.0 million recorded in 2020.
  • The sharpest move saw Net Cash Flow crashed 781.12% in 2021, then soared 543.45% in 2024.
  • Year by year, Net Cash Flow stood at $2.7 billion in 2020, then crashed by 391.59% to -$7.8 billion in 2021, then soared by 168.91% to $5.4 billion in 2022, then tumbled by 64.15% to $1.9 billion in 2023, then tumbled by 118.55% to -$356.0 million in 2024.
  • Business Quant data shows Net Cash Flow for TMO at -$356.0 million in Q4 2024, -$2.6 billion in Q3 2024, and $1.6 billion in Q2 2024.